MAIA Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Cash & Equivalents	7.15	10.95	10.57	0.66
Cash & Cash Equivalents	7.15	10.95	10.57	0.66
Cash Growth	-34.70%	3.56%	1493.82%	-
Other Current Assets	0.41	0.86	0.1	0.08
Total Current Assets	7.56	11.81	10.67	0.75
Other Long-Term Assets	0	0.21	0.65	0
Total Long-Term Assets	0	0.21	0.65	0
Total Assets	7.57	12.02	11.33	0.75
Accounts Payable	1.64	1.17	0.96	0.16
Current Debt	0	0	0	0.03
Other Current Liabilities	3.3	2.1	1.19	1.5
Total Current Liabilities	4.94	3.27	2.15	1.69
Long-Term Debt	0	0	0	0.46
Other Long-Term Liabilities	2.15	0.25	0	0.21
Total Long-Term Liabilities	2.15	0.25	0	0.67
Total Liabilities	7.09	3.51	2.15	2.36
Total Debt	0	0	0	0.49
Retained Earnings	-63.98	-44.21	-28.44	-15.93
Comprehensive Income	-0.02	-0.02	0	0
Shareholders' Equity	0.48	8.51	9.18	-3.34
Net Cash / Debt	7.15	10.95	10.57	0.17
Net Cash / Debt Growth	-34.70%	3.56%	5952.72%	-
Net Cash Per Share	0.54	1.18	2.00	0.04
Working Capital	2.63	8.54	8.53	-0.95
Book Value Per Share	0.04	0.92	1.74	-0.75

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).